Cancer screening in Spain

Ascunce, Nieves; Salas, Dolores; Zubizarreta, Raquel; Almazán, Raquel; Ibáñez, Josefa; Ederra, María

doi:10.1093/annonc/mdq085

Cited by 103 publications

(92 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women of 50-64 years of age are included in all programs, starting at 45 years or finishing at 69 years in some ACs. The mean overall participation was 67.0% [35]. Spain currently has a lower BC mortality rate among the European countries [18,36].…”

Section: Discussionmentioning

confidence: 99%

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Martín‐Sánchez

Clèries

Lidón

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

Background: Breast cancer (BC) is the main cause of cancer mortality among women, and mortality from lung cancer (LC) is increasing among women. The purpose of the present study was to project the mortality rates of both cancers and predict when LC mortality will exceed BC mortality. Methods: The cancer mortality data and female population distribution were obtained from the Spanish National Statistics Institute. Crude rate (CR), age-standardized rate (ASR), and age-specific rate were calculated for the period 1980-2013 and projected for the period 2014-2020 using a Bayesian log-linear Poisson model. Results: All calculated rates were greater for BC than for LC in 2013 (CR, 27.3 versus 17.3; ASR, 13.5 versus 9.3), and the CR was not projected to change by 2020 (29.2 versus 27.6). The ASR for LC is expected to surpass that of BC in 2019 (12.9 versus 12.7). Conclusions: By 2020 the LC mortality rates may exceed those of BC for ages 55-74 years, possibly because of the prevalence of smoking among women, and the screening for and more effective treatment of BC. BC screening could be a good opportunity to help smokers quit by offering counseling and behavioral intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Martín‐Sánchez

Clèries

Lidón

et al. 2016

Cancer Epidemiology

View full text Add to dashboard Cite

show abstract

“…In Spain, breast cancer screening follows the European Guidelines for Quality Assurance in Mammographic Screening [17] and its results meet the required standards [19,21]. Population-based breast cancer screening in Spain started in one region in 1990 and was implemented nationwide in 2006.…”

Section: Settingmentioning

confidence: 99%

Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening

Román

Sala

Vega

et al. 2011

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

False-positive results may influence adherence to mammography screening. The effectiveness of breast cancer screening is closely related to adequate adherence among the target population. The objective of this study was to evaluate how false-positives and women's characteristics affect the likelihood of reattendance at routine breast cancer screening in a sequence of routine screening invitations. We performed a retrospective cohort study of 1,371,218 women aged 45-69 years, eligible for the next routine screening, who underwent 4,545,346 screening mammograms from 1990 to 2006. We estimated the likelihood of attendance at seven sequential screening mammograms. Multilevel discrete time hazard models were used to estimate the effect of false-positive results on reattendance, and the odds ratios (OR) of non-attendance for the women's personal characteristics studied. The overall reattendance rate at the second screening was 81.7% while at the seventh screening was 95.6%. At the second screening invitation reattendance among women with and without a false-positive mammogram was 79.3 vs. 85.3%, respectively. At the fourth and seventh screenings, these percentages were 86.3 vs. 89.9% and 94.6 vs. 96.0%, respectively. The study variables associated with a higher risk of failing to participate in subsequent screenings were oldest age (OR = 8.48; 95% CI: 8.31-8.65), not attending their first screening invitation (OR = 1.12; 95% CI: 1.11-1.14), and previous invasive procedures (OR = 1.09; 95% CI: 1.07-1.10). The risk of non-attendance was lower in women with a familial history of breast cancer (OR = 0.97; 95% CI: 0.96-0.99), and those using hormone replacement therapy (OR = 0.96; 95% CI: 0.94-0.97). In conclusion, reattendance was lower in women with false-positive mammograms than in those with negative results, although this difference decreased with the number of completed screening participations, suggesting that abnormal results in earlier screenings more strongly influence behavior. These findings may be useful in providing women with accurate information and in improving the effectiveness of screening programs.

show abstract

“…1,6 Since 2003, the European Union has recommended population screening for breast and cervical cancers, and most countries have put different detection programmes into practice. 7 In 1990, Spanish public health authorities started a population screening programme for breast cancer offering a biennial mammogram to women aged 50e69 years with no family risk. Women with risk factors were invited to join the programme at 40 years of age.…”

Section: Introductionmentioning

confidence: 99%

Social disparities in access to breast and cervical cancer screening by women living in Spain

et al. 2015

View full text Add to dashboard Cite

Cancer screening in Spain

Cited by 103 publications

References 8 publications

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Bayesian prediction of lung and breast cancer mortality among women in Spain (2014–2020)

Effect of false-positives and women’s characteristics on long-term adherence to breast cancer screening

Social disparities in access to breast and cervical cancer screening by women living in Spain

Contact Info

Product

Resources

About